TITLE

The Myelodysplastic Syndromes: Diagnosis and Treatment

AUTHOR(S)
Steensma, David P.; Bennett, John M.
PUB. DATE
January 2006
SOURCE
Mayo Clinic Proceedings;Jan2006, Vol. 81 Issue 1, p104
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The myelodysplastic syndromes (MDS5) are common, acquired, clinically challenging hematologic conditions that are characterized by bone marrow failure and a risk of progression to acute leukemia. These disorders can arise de novo, especially in elderly patients or, less often, as a consequence of prior chemotherapy or radiotherapy for an unrelated disease. The MDS classification systems were revised recently and updated. These refined classification and prognostic schemes help stratify patients by their risk of leukemia progression and death; this knowledge can help clinicians select appropriate therapy. Although many treatments for MDS have been proposed and evaluated, at present, only hematopoietic stem cell transplantation offers any real hope for cure, and no available therapy beyond general supportive care offers benefit to more than a minority of patients. However, recent clinical trials enrolling patients with MDS have reported encouraging results with use of newer drugs, including lenalidomide, decitabine, and darbepoetin alfa. Other exciting treatment regimens are being tested. Here, we present a contemporary, practical clinical approach to the diagnosis and risk-stratified treatment of MDS. We review when to suspect MDS, detail how to evaluate patients who may have a form of the condition, explain key features of treatments that are currently available in the United States, and summarize a general, common-sense therapeutic approach to patients with MDS.
ACCESSION #
19800793

 

Related Articles

  • The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Matarraz, S.; López, A.; Barrena, S.; Fernandez, C.; Jensen, E.; Flores, J.; Bárcena, P.; Rasillo, A.; Sayagues, J. M.; Sánchez, M. L.; Hernandez-Campo, P.; Rivas, J. M. Hernandez; Salvador, C.; Fernandez-Mosteirín, N.; Giralt, M.; Perdiguer, L.; Orfao, A. // Leukemia (08876924);Jun2008, Vol. 22 Issue 6, p1175 

    Occurrence of phenotypic abnormalities in CD34+ hematopoietic progenitor and precursor cells (HPC) and their major B-cell and nonlymphoid compartments has been frequently reported in myelodysplastic syndromes (MDS). Here, we analyze for the first time the numerical and phenotypic abnormalities...

  • Evaluation of BM cytomorphology after allo-SCT in patients with MDS. Christopeit, M; Ocheni, S; Haferlach, T; Miersch, K; Zabelina, T; Klyuchnikov, E; Binder, M; Ayuk, F; Schafhausen, P; Zander, A R; Bokemeyer, C; Kröger, N; Bacher, U // Bone Marrow Transplantation;Mar2013, Vol. 48 Issue 3, p465 

    The article presents a study which describes the disease status of bone marrow (BM) cytomorphology in patients with myelodysplastic syndromes (MDS). It describes the blast count, dysplasia, and cellularity in stem cell recipients following an allogeneic haematopoietic SCT. The study implies that...

  • Targeting Immune Dysregulation in Myelodysplastic Syndromes. Olnes, Matthew J.; Sloand, Elaine M. // JAMA: Journal of the American Medical Association;2/23/2011, Vol. 305 Issue 8, p814 

    The article describes the case of a 56-year-old woman with myelodysplastic syndrome (MDA). She complained of fatigue and easy bruising for several weeks. She became progressively anemic and leukopenic over the next five months. She was treated with granulocyte colony-stimulating factor. The...

  • 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Field, T.; Perkins, J.; Huang, Y.; Kharfan-Dabaja, M. A.; Alsina, M.; Ayala, E.; Fernandez, H. F.; Janssen, W.; Lancet, J.; Perez, L.; Sullivan, D.; List, A.; Anasetti, C. // Bone Marrow Transplantation;Feb2010, Vol. 45 Issue 2, p255 

    Relapse remains a leading cause for treatment failure after hematopoietic cell transplantation (HCT) in patients with intermediate- or high-risk myelodysplastic syndrome (MDS). To discern the impact of 5-azacitine treatment pretransplant on the risk for relapse after HCT, we analyzed the post...

  • 5q— myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Eisenmann, K. M.; Dykema, K. J.; Matheson, S. F.; Kent, N. F.; DeWard, A. D.; West, R. A.; Tibes, R.; Furge, K. A.; Alberts, A. S. // Oncogene;10/1/2009, Vol. 28 Issue 39, p3429 

    Complete loss or interstitial deletions of chromosome 5 are the most common karyotypic abnormality in myelodysplastic syndromes (MDSs). Isolated del(5q)/5q– MDS patients have a more favorable prognosis than those with additional karyotypic defects, who tend to develop myeloproliferative...

  • Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Chen, B.; Zhao, W.-L.; Jin, J.; Xue, Y.-Q.; Cheng, X.; Chen, X.-T.; Cui, J.; Chen, Z.-M.; Cao, Q.; Yang, G.; Yao, Y.; Xia, H.-L.; Tong, J.-H.; Li, J.-M.; Chen, J.; Xiong, S.-M.; Shen, Z.-X.; Waxman, S.; Chen, Z.; Chen, S.-J. // Leukemia (08876924);May2005, Vol. 19 Issue 5, p767 

    Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis and leukemia progression. Racial differences may exist on clinical pictures and the molecular events leading to MDS, which are heterogeneous. To better define the clinical and...

  • Myelodysplasia: battle in the bone marrow. Yan Liu; Asai, Takashi; Nimer, Stephen D. // Nature Medicine;Jan2010, Vol. 16 Issue 1, p30 

    The article presents a study conducted by Barlow and Starczynowski concerning the pathogenesis of the myelodysplastic syndrome (MDS). The researchers examined the decreased expression of MicroRNA-145 (miR) and miR-146a in bone marrow cells from people with MDS in which they discovered that lack...

  • Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Kurosawa, S; Yakushijin, K; Yamaguchi, T; Atsuta, Y; Nagamura-Inoue, T; Akiyama, H; Taniguchi, S; Miyamura, K; Takahashi, S; Eto, T; Ogawa, H; Kurokawa, M; Tanaka, J; Kawa, K; Kato, K; Suzuki, R; Morishima, Y; Sakamaki, H; Fukuda, T // Bone Marrow Transplantation;Apr2013, Vol. 48 Issue 4, p529 

    The outcomes for allogeneic hematopoietic cell transplantation (allo-HCT) are heavily influenced by non-relapse mortality (NRM). We retrospectively assessed the changes in the incidence and causes of NRM after allo-HCT over the past 12 years. NRM, relapse rate and OS were analyzed using the...

  • Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges. Bierings, Marc; Nachman, James B.; Zwaan, C. Michel // Current Stem Cell Research & Therapy;Jan2007, Vol. 2 Issue 1, p53 

    The role of stem cell transplantation in the treatment of leukemia and myelodysplasia (MDS) in children has changed over the past decade. In pediatric acute lymphoblastic leukemia (ALL), the overall curerate is high with conventional chemotherapy. However, selected patients with a high-risk of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics